Table 3.
Correlational analysis between regional changes in μ-opioid BPND and pain reports after placebo administration.
DLPFC | mOFC | lOFC | IFG | rACC | sgACC | pINS | PHipp | NAc | dPUT | vPUT | aTHA | ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
H | R | L | R | L | L | L | L | R | L | R | R | R | R | R | |
Δ MPQ | r | .19 | .24 | .42 | .39 | .16 | .30 | .37 | .45 | .18 | .42 | .38 | .35 | .36 | .40 |
Total | Sig. | .2 | .1 | .005* | .01* | .3 | .01* | .01* | .01* | .3 | .005* | .01* | .02* | .02* | .01* |
Δ MPQ Pain | r | .30 | .30 | .41 | .39 | .25 | .21 | .29 | .31 | .32 | .33 | .40 | .31 | .34 | .34 |
Affect | Sig. | .057 | .04* | .007* | .01* | .1 | .2 | .065 | .04* | .03* | .03* | .008* | .04* | .02* | .02* |
Δ MPQ | r | .15 | .22 | .33 | .34 | .10 | .30 | .41 | .40 | .09 | .41 | .33 | .34 | .35 | .38 |
Sensory | Sig. | .3 | .2 | .03* | .02* | .5 | .01* | .006* | .007* | .6 | .006* | .03* | .03* | .02* | .01* |
Δ MPQ Pain | r | .40 | .28 | .33 | .38 | .37 | .22 | .31 | .12 | .18 | .23 | .27 | .24 | .24 | .24 |
Affect at 24h | Sig. | .006* | .080 | .042 | .017* | .02* | .2 | .052 | .5 | .3 | .2 | .094 | .1 | .1 | .1 |
Abbreviations: DLPFC: dorsolateral prefrontal cortex; mOFC and lOFC: medial and lateral orbitofrontal cortex; IFG: Inferior frontal gyrus; sgACC and rACC: subgenual and rostral anterior cingulate cortex; aINS and pINS: anterior and posterior insula; PHipp: Parahippocampus; NAc: nucleus accumbens; dPUT and vPUT: dorsal and anterior putamen; aTHA: anterior thalamus.